Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 17/20 | 0.37 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033718 | 1.00 | XIAP (0.37) | XIAPBIRC3BIRC2F2PLG | |
| SCHEMBL6033112 | 1.00 | XIAP (0.37) | XIAPBIRC3BIRC2F2PLG | |
| SCHEMBL6033714 | 1.00 | XIAP (0.37) | XIAPBIRC3BIRC2F2PLG | |
| SCHEMBL6063191 | 0.75 | PREP (0.41) | F2PLG | |
| SCHEMBL6062550 | 0.75 | PREP (0.41) | F2PLG | |
| SCHEMBL6034367 | 0.75 | PREP (0.38) | — | |
| SCHEMBL6062543 | 0.75 | PREP (0.41) | F2PLG | |
| SCHEMBL6034365 | 0.75 | PREP (0.38) | — | |
| SCHEMBL6012053 | 0.74 | XIAP (0.30) | XIAPF2PLG | |
| SCHEMBL22478996 | 0.72 | XIAP (0.48) | XIAPBIRC3BIRC2F2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094800-B2 | pyrrolizinones, e.g., (3S,6R,7aS)-6-amino-5-oxo-hexahydro-pyrrolizine-3-carbonitrile trifluoroacetate, used for reducing blood sugar, treating type 2 diabetes, and treating insulin resistance | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-22 | — | — | US | disclosed |
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059724-A1 | Novel cyanopyrrolidides, process for their preparation and their use as medicaments | CYP11B2, SLC5A2, CYP11B1 | XIAP 2346/4885BIRC3 2262/4885BIRC2 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.